In clinical practice, we often observe an interesting phenomenon: cancers that seem unrelated—such as lung cancer, melanoma, liver cancer, esophageal cancer, stomach cancer, and kidney cancer—with distinct locations (lung, skin, digestive tract) and pathological features, frequently "team up" on the indication list of the same drug, as if "successfully grouping a purchase" in the treatment plan.
It was not until I read relevant articles and materials on the official website of DengYue Medicine that I realized this is no coincidence. These cancers share a common "fatal weakness," which is the core reason why the drug Nivolumab can exert cross-border effects.
Cancer's “Disguise Tactics”: The Key Trick to Fooling the Immune System
The reason these cancers can break through the immune system's defenses and become intractable diseases lies in their being "Oscar-worthy pretenders." Our immune system is like a diligent "all-around security team." Under normal circumstances, it conducts strict "identity checks" on cells in the body: normal cells with clear identities are allowed to pass; abnormal cells (such as bacteria and viruses) trigger an immediate defense response and are eliminated on the spot. However, the aforementioned cancer cells are masters of "disguise." They are adept at pretending to be innocent in front of immune cells, misleading them with a false signal: "Relax, I'm one of your own!"
More cunningly, they secretly present "forged passes"—PD-L1/PD-L2 proteins—to immune cells, equivalent to issuing a "no action" order to the security team that should be actively fighting. As a result, even though immune cells have long detected the cancer cells and even surrounded them, they dare not launch an attack, deceived by the pretense of being "one of their own."
The Core of Intractability: Not “Uncatchable,” but “Not Allowed to Catch”
Many people mistakenly believe these cancers are difficult to cure because the immune system is too weak to fight them, or because cancer cells are hiding too deeply to be found. But the truth is quite the opposite: immune cells have not only long seen through the cancer cells' true colors but also completed their encirclement.
The real problem is not "being unable to catch them," but "not being allowed to catch them"—cancer cells have successfully pressed the "pause button" on the immune system through disguise. The emergence of Nivolumab is precisely to unlock this pressed "pause button."
Opdivo（Nivolumab）’s “Unlocking Logic”: Activating the Immune System to Fight Cancer
As a PD-1 immune checkpoint inhibitor, Opdivo does not directly attack cancer cells like traditional anti-cancer drugs, nor does it "forcefully buff" the immune system. Instead, it targets the core of the problem: it specifically binds to the PD-1 receptor on the surface of T cells, blocking the interaction between cancer cells' PD-L1/PD-L2 proteins and PD-1.
This is equivalent to declaring to the deceived immune cells: "The previous 'no action' order is revoked! You can start working now!" With this "unlocking command," the suppressed T cells instantly "regain consciousness," restoring their inherent anti-tumor activity. The immune response restarts, and the body's own "security team" can finally fight cancer cells without restraint. Essentially, Nivolumab is not an external "special forces reinforcement," but a key role that helps the immune system "tear off the cancer cells' disguise and lift immune suppression."
The Secret of Cross-Border Indications: Precisely Targeting One Type of Cancer
This explains why Nivolumab's indications are so "cross-border." As long as a cancer meets three core conditions—it can be recognized by the immune system (not completely undetectable), cancer cells use "disguise tactics" to deceive the immune system (successfully pressing the immune pause button), and traditional treatments (such as chemotherapy and radiotherapy) have limited effects—it may appear on Nivolumab's indication list.
It is not a "panacea for all cancers" and will not work for every type of cancer. Instead, it precisely targets the category of cancers that "excel at deceiving the immune system." Whether these cancers are located in the lung, skin, or digestive tract, as long as their "deception tactics" are consistent, Nivolumab can be effective.
Important Reminder: Immunotherapy Is Not Suitable for Everyone
Of course, we need to clarify an important premise: while immunotherapy is effective, it is not suitable for everyone. Whether Nivolumab is appropriate depends on a comprehensive evaluation by doctors based on the patient's specific condition, tumor characteristics, immune status, and other factors, confirming that it meets the core conditions of "immune accessibility and being deceived by the tumor." During treatment, patients need to cooperate with doctors for regular monitoring, focusing on immune-related adverse reactions (such as thyroid dysfunction, immune-mediated pneumonia, hepatitis, etc.). Under no circumstances should patients self-administer the drug or discontinue it arbitrarily.
Hope from Medical Progress: Rewriting the Pattern of Advanced Cancer Treatment
Despite limitations in its scope of application, the emergence of Nivolumab has rewritten the fate of countless patients with advanced cancer. It has brought the possibility of "long-term control" to advanced cancers that were once "untreatable," and alleviated the dilemma of "killing a thousand enemies and losing eight hundred" in traditional treatments. By activating the body's own immunity, it achieves gentler and more targeted anti-cancer treatment. On the long and arduous road of fighting cancer, every medical progress injects new hope into patients—and immunotherapy represented by Nivolumab is one of the brightest lights of that hope.
Knowledge Is Also "Immunity" in the Fight Against Cancer.After reading this article, you may finally understand: the reason those seemingly unrelated cancers can share a single drug is that medicine has found their common "Achilles' heel"—deceiving the immune system. Nivolumab exists to break this deception with wisdom and reactivate the body's "endogenous power."
If you have friends or relatives fighting cancer, feel free to share this popular science article with them. More understanding of treatment options means less fear of the unknown. Medicine is advancing, and anti-cancer weapons are constantly upgrading. May every persistence meet hope, and every effort be rewarded with health and well-being.
No comments:
Post a Comment